RHINOCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHINOCORT (RHINOCORT).
Corticosteroid that inhibits inflammatory mediators (e.g., prostaglandins, leukotrienes) and reduces nasal mucosa inflammation.
| Metabolism | Hepatic via CYP3A4; undergoes first-pass metabolism. |
| Excretion | Budesonide (active ingredient) is primarily eliminated via hepatic metabolism (CYP3A4) with metabolites excreted in urine (60%) and feces (40%). Unchanged drug in urine is less than 10%. |
| Half-life | Terminal elimination half-life is 2.0–3.6 hours in adults, allowing twice-daily dosing. |
| Protein binding | 85–90% bound to albumin. |
| Volume of Distribution | 2.2–3.9 L/kg; extensive tissue distribution. |
| Bioavailability | Intranasal: ~34% (due to first-pass metabolism). Oral inhalation: ~11%. Oral: <1%. |
| Onset of Action | Intranasal: 3–7 hours for first dose; peak effect may take 1–2 weeks. |
| Duration of Action | Intranasal: ~12 hours; clinical improvement sustained with regular use. |
| Molecular Weight | 430.5 |
2 sprays (64 mcg) per nostril once daily, or 1 spray (32 mcg) per nostril twice daily; intranasal use.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Children 6-12 years: 1 spray (32 mcg) per nostril once daily; some guidelines allow up to 2 sprays per nostril once daily if needed. Children ≥12 years: same as adult. |
| Geriatric use | No specific adjustment; initiate at lower end of dosing range due to potential increased sensitivity. |
| 1st trimester | Avoid unless clearly needed; limited human data, but corticosteroids are teratogenic in animals. |
| 2nd trimester | Use only if potential benefit outweighs risk; minimal systemic absorption. |
| 3rd trimester | Use only if potential benefit outweighs risk; minimal systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for RHINOCORT (RHINOCORT).
| Placental transfer | Minimal due to low systemic bioavailability; negligible placental crossing expected. |
| Breastfeeding | Minimal systemic absorption; unlikely to affect breastfed infant. Use lowest effective dose. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Untreated nasal mucosal infection (e.g., herpes simplex)Recent nasal surgery or trauma until healed
| Precautions | Nasal septal perforation, Impaired wound healing, Increased intraocular pressure/glaucoma, Cataracts, Adrenal suppression with high doses, Growth retardation in children |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase systemic budesonide levels via CYP3A4 inhibition, but minimal due to low bioavailability. No dietary restrictions needed. |
| Clinical Pearls |
Loading safety data…
| L2 |
| Teratogenic Risk | Budesonide (Rhinocort) is classified as Pregnancy Category B. No teratogenic effects have been observed in animal studies at doses up to 100 times the maximum human intranasal dose. In human studies, inhaled budesonide during pregnancy showed no increased risk of congenital malformations. However, intranasal administration results in negligible systemic absorption, minimizing fetal exposure. Nonetheless, use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. However, monitor for systemic corticosteroid effects if used long-term or at high doses, including adrenal suppression, growth retardation in fetus, and maternal hyperglycemia. Nasal examination periodically for mucosal changes. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data with intranasal budesonide. Systemic corticosteroids may impair fertility, but intranasal route yields negligible systemic exposure. |
| Rhinocort (budesonide) is an intranasal corticosteroid for allergic rhinitis. Onset of action is 10-12 hours, with maximal effect after several days. Use regularly for best results, not PRN. Advise patients to blow nose gently before use and aim spray away from nasal septum to reduce risk of epistaxis. Monitor for nasal septal perforation with long-term use. Can be used with antihistamines. |
| Patient Advice | Use regularly, not just as needed, for best effect. · Blow nose gently before each use. · Shake the bottle gently before use. · Tilt head forward slightly and spray into nostril, aiming away from the septum. · Do not spray onto the nasal septum to prevent bleeding. · Rinse the nozzle with warm water after each use and replace cap. · Clean the nozzle weekly. · Do not share the medication with others. · Notify your doctor if you have frequent nosebleeds, crusting, or pain. · Do not stop suddenly; may need gradual reduction if used long-term. |